

**Adbry™ (tralokinumab-ldrm) Prior Authorization Form**

Member Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_ Member ID#: \_\_\_\_\_

**Drug Information**

Pharmacy billing (NDC: \_\_\_\_\_) Fill Date: \_\_\_\_\_

Dose: \_\_\_\_\_ Regimen: \_\_\_\_\_

**Pharmacy Information**

Pharmacy NPI: \_\_\_\_\_ Pharmacy Name: \_\_\_\_\_

Pharmacy Phone: \_\_\_\_\_ Pharmacy Fax: \_\_\_\_\_

**Prescriber Information**

Prescriber NPI: \_\_\_\_\_ Prescriber Name: \_\_\_\_\_

Prescriber Phone: \_\_\_\_\_ Prescriber Fax: \_\_\_\_\_ Specialty: \_\_\_\_\_

**Clinical Information**
**For Initial Authorization: (Initial approval will be for the duration of 16 weeks)**

1. Diagnosis of moderate-to-severe atopic dermatitis? Yes ☐ No ☐
2. Member's body surface area (BSA) of atopic dermatitis involvement: \_\_\_\_\_
3. Is member inadequately controlled with topical prescription therapies? Yes ☐ No ☐
4. Is there a reason topical treatment is not advised? Yes ☐ No ☐
  - i. If yes, please describe: \_\_\_\_\_
5. Has the member failed 1 medium potency to very-high potency Tier-1 topical corticosteroid? Yes ☐ No ☐
  - i. If yes, please provide the medication and duration of treatment:
    - a. Drug: \_\_\_\_\_ Date of trial: \_\_\_\_\_
    - b. Was the trial at least 2 weeks in duration? Yes ☐ No ☐
  - ii. If no, is there a contraindication or documented intolerance to medium potency to very-high potency Tier-1 topical corticosteroids? Yes ☐ No ☐
    - a. If yes, please describe: \_\_\_\_\_
6. Has the member failed 1 topical calcineurin inhibitor (e.g., pimecrolimus or tacrolimus)? Yes ☐ No ☐
  - i. If yes, please provide the medication and duration of treatment:
    - a. Drug: \_\_\_\_\_ Date of trial: \_\_\_\_\_
    - b. Was the trial at least 2 weeks in duration? Yes ☐ No ☐
  - ii. If no, is there a contraindication or documented intolerance to topical calcineurin inhibitors? Yes ☐ No ☐
    - a. If yes, please describe: \_\_\_\_\_
7. Will the member be using Adbry™ concurrently with other biologic medications? Yes ☐ No ☐
  - i. If yes, please provide patient-specific information to support the concurrent use of medications: \_\_\_\_\_
8. Has the member been evaluated by an allergist, dermatologist or immunologist within the last 12 months (or an advanced care practitioner with a supervising physician who is one of these specialties)? Yes ☐ No ☐
  - i. If yes, please include name of specialist: \_\_\_\_\_ Specialty: \_\_\_\_\_

**For Continued Authorization:**

1. Is member compliant with therapy? Yes ☐ No ☐
2. Is member responding well to therapy? Yes ☐ No ☐

**Please do not send in chart notes. Specific information/documentation will be requested if necessary.**  
**Please complete and return all pages. Failure to complete all pages will result in processing delays.**

 Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
 By signature, the physician confirms the criteria information above is accurate and verifiable in patient records.)

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at [AetnaBetterHealth.com/Oklahoma](http://AetnaBetterHealth.com/Oklahoma).

**CONFIDENTIALITY NOTICE**  
 This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.